VEGFD (VEGF4) (AA 89-205) antibody

Catalog No. ABIN4953063

This Rabbit Polyclonal antibody specifically detects in IHC (p) and WB. It exhibits reactivity toward Human.

Quick Overview for VEGFD (VEGF4) (AA 89-205) antibody (ABIN4953063)

Target: VEGFD (VEGF4)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: Un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)

Product Details

Binding Specificity: AA 89-205

Purification: Antigen affinity

Immunogen: Amino acids 89-205 of human VEGFD were used as the immunogen for the VEGFD antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the VEGFD antibody should be determined by the researcher.\. Western blot: 0.1-0.5 μg/mL,IHC (FFPE): 1-2 μg/mL

Restrictions: For Research Use only

Handling

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: -20 °C

Storage Comment: After reconstitution, the VEGFD antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Target Details

Target: VEGFD (VEGF4)

Alternative Name: VEGFD / VEGF4

Background: C-fos induced growth factor (FIGF) (or vascular endothelial growth factor D, VEGFD, VEGF4) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene. The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. Analyzing by Northern blotting, Yamada et al. (1997) symbolized VEGFD, was expressed as a 2.2-kb transcript with highest expression in lung, heart, small intestine, and fetal lung, and lower levels in skeletal muscle, colon, and pancreas. And Achen et al. (1998) concluded that VEGFD was most closely related to VEGFC by virtue of the presence of N- and C-terminal extensions that were not found in other VEGF family members. Stacker et al. (2001) showed that VEGFD can induce tumor angiogenesis through VEGFR2 and tumor lymphangiogenesis through VEGFR3, whereas VEGF, which does not activate VEGFR3, induces only tumor angiogenesis.

UniProt: O43915